25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

PCSA (Processa Pharmaceuticals Inc) Stock Analysis
Buy, Hold or Sell?

Let's analyze Processa Pharmaceuticals Inc together

I guess you are interested in Processa Pharmaceuticals Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • πŸ“Š Fundamental Analysis (FA) – Processa Pharmaceuticals Inc’s Financial Insights
  • πŸ“ˆ Technical Analysis (TA) – Processa Pharmaceuticals Inc’s Price Targets

I'm going to help you getting a better view of Processa Pharmaceuticals Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Processa Pharmaceuticals Inc

I send you an email if I find something interesting about Processa Pharmaceuticals Inc.

1. Quick Overview

1.1. Quick analysis of Processa Pharmaceuticals Inc (30 sec.)










1.2. What can you expect buying and holding a share of Processa Pharmaceuticals Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
5.0%

What is your share worth?

Current worth
$0.13
Expected worth in 1 year
$-0.07
How sure are you?
27.5%

+ What do you gain per year?

Total Gains per Share
$-0.20
Return On Investment
-90.4%

For what price can you sell your share?

Current Price per Share
$0.23
Expected price per share
$0.15 - $0.708
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Processa Pharmaceuticals Inc (5 min.)




Live pricePrice per Share (EOD)
$0.23
Intrinsic Value Per Share
$-4.51 - $-3.14
Total Value Per Share
$-4.37 - $-3.01

2.2. Growth of Processa Pharmaceuticals Inc (5 min.)




Is Processa Pharmaceuticals Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$3.5m$7.5m-$3.8m-101.8%

How much money is Processa Pharmaceuticals Inc making?

Current yearPrevious yearGrowGrow %
Making money-$2.9m-$2.4m-$533k-17.8%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

2.3. Financial Health of Processa Pharmaceuticals Inc (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#668 / 872

Most Revenue
#673 / 872

Most Profit
#338 / 872

Most Efficient
#370 / 872
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Processa Pharmaceuticals Inc?

Welcome investor! Processa Pharmaceuticals Inc's management wants to use your money to grow the business. In return you get a share of Processa Pharmaceuticals Inc.

First you should know what it really means to hold a share of Processa Pharmaceuticals Inc. And how you can make/lose money.

Speculation

The Price per Share of Processa Pharmaceuticals Inc is $0.2262. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Processa Pharmaceuticals Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Processa Pharmaceuticals Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $0.13. Based on the TTM, the Book Value Change Per Share is $-0.05 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.01 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Processa Pharmaceuticals Inc.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.11-47.8%-0.11-50.5%-0.09-41.5%-0.12-53.7%-0.14-59.9%-0.08-34.3%
Usd Book Value Change Per Share0.0730.9%-0.05-22.6%-0.01-5.3%-0.06-27.7%-0.01-3.1%0.001.2%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.0730.9%-0.05-22.6%-0.01-5.3%-0.06-27.7%-0.01-3.1%0.001.2%
Usd Price Per Share0.37-1.22-0.86-1.25-3.80-3.32-
Price to Earnings Ratio-0.85--2.62--2.16--2.43--10.98--30.03-
Price-to-Total Gains Ratio5.29--10.56--1.17--7.43--48.93--74.94-
Price to Book Ratio2.75-8.95-2.77-4.92-9.12-15.18-
Price-to-Total Gains Ratio5.29--10.56--1.17--7.43--48.93--74.94-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.2262
Number of shares4420
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.05-0.01
Usd Total Gains Per Share-0.05-0.01
Gains per Quarter (4420 shares)-225.97-31.28
Gains per Year (4420 shares)-903.89-125.12
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-904-9140-125-135
20-1808-18180-250-260
30-2712-27220-375-385
40-3616-36260-500-510
50-4519-45300-626-635
60-5423-54340-751-760
70-6327-63380-876-885
80-7231-72420-1001-1010
90-8135-81460-1126-1135
100-9039-90500-1251-1260

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.040.00.00.0%0.054.00.00.0%
Book Value Change Per Share1.03.00.025.0%3.09.00.025.0%5.015.00.025.0%11.028.01.027.5%14.036.04.025.9%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%2.00.038.05.0%5.00.049.09.3%
Total Gains per Share1.03.00.025.0%3.09.00.025.0%5.015.00.025.0%11.028.01.027.5%14.036.04.025.9%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Processa Pharmaceuticals Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.070-0.051+173%-0.012+117%-0.063+190%-0.007+110%0.003+2492%
Book Value Per Share--0.1350.143-6%0.288-53%0.318-58%0.519-74%0.319-58%
Current Ratio--2.9293.235-9%9.757-70%7.003-58%9.540-69%5.341-45%
Debt To Asset Ratio--0.2670.299-11%0.112+137%0.176+52%0.161+65%41.376-99%
Debt To Equity Ratio--0.3640.464-22%0.127+186%0.242+50%0.227+60%1.494-76%
Dividend Per Share----0%-0%-0%-0%0.000-100%
Enterprise Value--11306034.00033585135.180-66%28939970.530-61%38067011.523-70%107445574.964-89%106183444.332-89%
Eps---0.108-0.114+5%-0.094-13%-0.122+12%-0.136+25%-0.078-28%
Ev To Ebitda Ratio---0.993-2.726+175%-2.713+173%-2.639+166%-12.701+1179%-17.133+1626%
Free Cash Flow Per Share---0.104-0.114+9%-0.076-27%-0.095-9%-0.082-21%-0.050-52%
Free Cash Flow To Equity Per Share--0.065-0.057+188%-0.017+127%-0.037+156%0.005+1154%0.003+1842%
Gross Profit Margin--1.0001.000+0%1.0000%1.0000%1.0000%1.054-5%
Intrinsic Value_10Y_max---3.144----------
Intrinsic Value_10Y_min---4.506----------
Intrinsic Value_1Y_max---0.216----------
Intrinsic Value_1Y_min---0.395----------
Intrinsic Value_3Y_max---0.724----------
Intrinsic Value_3Y_min---1.242----------
Intrinsic Value_5Y_max---1.324----------
Intrinsic Value_5Y_min---2.144----------
Market Cap5925173.280-64%9691928.00031851080.680-70%22574988.780-57%32701962.107-70%99599229.064-90%87034954.132-89%
Net Profit Margin----0%-0%-0%0.844-100%-11.4970%
Operating Margin----0%-0%-0%0.900-100%-12.0240%
Operating Ratio----0%-0%-0%-0.8970%10.508-100%
Pb Ratio1.680-64%2.7488.946-69%2.767-1%4.925-44%9.122-70%15.182-82%
Pe Ratio-0.523+39%-0.855-2.625+207%-2.156+152%-2.430+184%-10.980+1184%-30.030+3413%
Price Per Share0.226-64%0.3701.216-70%0.862-57%1.248-70%3.802-90%3.323-89%
Price To Free Cash Flow Ratio-0.543+39%-0.888-2.584+191%-2.774+213%-3.228+264%94.003-101%5.727-115%
Price To Total Gains Ratio3.237-64%5.295-10.560+299%-1.167+122%-7.426+240%-48.932+1024%-74.937+1515%
Quick Ratio--2.2582.249+0%8.540-74%5.826-61%8.425-73%4.915-54%
Return On Assets---0.589-0.629+7%-0.302-49%-0.510-14%-0.371-37%-2.000+239%
Return On Equity---0.804-0.955+19%-0.341-58%-0.661-18%-0.478-40%-0.944+17%
Total Gains Per Share--0.070-0.051+173%-0.012+117%-0.063+190%-0.007+110%0.003+2472%
Usd Book Value--3526608.0003741807.000-6%7550021.500-53%8341849.667-58%13583504.150-74%8364150.825-58%
Usd Book Value Change Per Share--0.070-0.051+173%-0.012+117%-0.063+190%-0.007+110%0.003+2492%
Usd Book Value Per Share--0.1350.143-6%0.288-53%0.318-58%0.519-74%0.319-58%
Usd Dividend Per Share----0%-0%-0%-0%0.000-100%
Usd Enterprise Value--11306034.00033585135.180-66%28939970.530-61%38067011.523-70%107445574.964-89%106183444.332-89%
Usd Eps---0.108-0.114+5%-0.094-13%-0.122+12%-0.136+25%-0.078-28%
Usd Free Cash Flow---2729848.000-2982312.500+9%-2000234.000-27%-2487206.083-9%-2148171.650-21%-1300853.475-52%
Usd Free Cash Flow Per Share---0.104-0.114+9%-0.076-27%-0.095-9%-0.082-21%-0.050-52%
Usd Free Cash Flow To Equity Per Share--0.065-0.057+188%-0.017+127%-0.037+156%0.005+1154%0.003+1842%
Usd Market Cap5925173.280-64%9691928.00031851080.680-70%22574988.780-57%32701962.107-70%99599229.064-90%87034954.132-89%
Usd Price Per Share0.226-64%0.3701.216-70%0.862-57%1.248-70%3.802-90%3.323-89%
Usd Profit---2834405.000-2989535.500+5%-2456457.000-13%-4163869.417+47%-3907948.400+38%-2283151.275-19%
Usd Revenue----0%-0%-0%-5127.5000%920.391-100%
Usd Total Gains Per Share--0.070-0.051+173%-0.012+117%-0.063+190%-0.007+110%0.003+2472%
 EOD+2 -6MRQTTM+22 -11YOY+10 -233Y+13 -205Y+14 -2110Y+16 -21

3.3 Fundamental Score

Let's check the fundamental score of Processa Pharmaceuticals Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.523
Price to Book Ratio (EOD)Between0-11.680
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than12.258
Current Ratio (MRQ)Greater than12.929
Debt to Asset Ratio (MRQ)Less than10.267
Debt to Equity Ratio (MRQ)Less than10.364
Return on Equity (MRQ)Greater than0.15-0.804
Return on Assets (MRQ)Greater than0.05-0.589
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of Processa Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5046.567
Ma 20Greater thanMa 500.240
Ma 50Greater thanMa 1000.259
Ma 100Greater thanMa 2000.325
OpenGreater thanClose0.220
Total0/5 (0.0%)

4. In-depth Analysis

4.1 About Processa Pharmaceuticals Inc

Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine, which is in Phase 2 clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers. It also develops non-oncology drugs consisting of PCS12852 that is in Phase 2B clinical trials for treatment of gastroparesis; and PCS499 for the treatment of glomerular disease. The company has license agreements with Elion Oncology, Inc.; Ocuphire Pharma, Inc.; Aposense, Ltd.; Yuhan Corporation; and CoNCERT Pharmaceuticals, Inc. Processa Pharmaceuticals, Inc. was founded in 2017 and is based in Hanover, Maryland.

Fundamental data was last updated by Penke on 2025-07-12 08:25:06.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is overpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitΒ Processa Pharmaceuticals Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compareΒ Processa Pharmaceuticals Inc to theΒ Biotechnology industry mean.
  • A Net Profit Margin of 0.0%Β means thatΒ $0.00 for each $1Β in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Processa Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y84.4%-84.4%
5Y84.4%10Y-1,149.7%+1,234.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--93.6%+93.6%
TTM--140.9%+140.9%
YOY--197.6%+197.6%
3Y--248.5%+248.5%
5Y84.4%-343.4%+427.8%
10Y-1,149.7%-496.2%-653.5%
4.3.1.2. Return on Assets

Shows howΒ efficientΒ Processa Pharmaceuticals Inc is using its assets to generate profit.

  • Above 5% is considered healthyΒ but always compareΒ Processa Pharmaceuticals Inc to theΒ Biotechnology industry mean.
  • -58.9% Return on Assets means thatΒ Processa Pharmaceuticals Inc generatedΒ $-0.59 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Processa Pharmaceuticals Inc:

  • The MRQ is -58.9%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -62.9%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-58.9%TTM-62.9%+3.9%
TTM-62.9%YOY-30.2%-32.7%
TTM-62.9%5Y-37.1%-25.8%
5Y-37.1%10Y-200.0%+163.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-58.9%-11.6%-47.3%
TTM-62.9%-11.6%-51.3%
YOY-30.2%-11.4%-18.8%
3Y-51.0%-11.8%-39.2%
5Y-37.1%-12.0%-25.1%
10Y-200.0%-13.7%-186.3%
4.3.1.3. Return on Equity

Shows how efficient Processa Pharmaceuticals Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareΒ Processa Pharmaceuticals Inc to theΒ Biotechnology industry mean.
  • -80.4% Return on Equity means Processa Pharmaceuticals Inc generated $-0.80Β for eachΒ $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Processa Pharmaceuticals Inc:

  • The MRQ is -80.4%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -95.5%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-80.4%TTM-95.5%+15.2%
TTM-95.5%YOY-34.1%-61.4%
TTM-95.5%5Y-47.8%-47.7%
5Y-47.8%10Y-94.4%+46.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-80.4%-13.5%-66.9%
TTM-95.5%-14.9%-80.6%
YOY-34.1%-14.6%-19.5%
3Y-66.1%-16.8%-49.3%
5Y-47.8%-17.5%-30.3%
10Y-94.4%-19.9%-74.5%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Processa Pharmaceuticals Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

MeasuresΒ how efficient Processa Pharmaceuticals Inc is operatingΒ .

  • Measures how much profit Processa Pharmaceuticals Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareΒ Processa Pharmaceuticals Inc to theΒ Biotechnology industry mean.
  • An Operating Margin of 0.0%Β means the company generated $0.00 Β for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Processa Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y90.0%-90.0%
5Y90.0%10Y-1,202.4%+1,292.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--232.5%+232.5%
TTM--250.5%+250.5%
YOY--209.2%+209.2%
3Y--234.1%+234.1%
5Y90.0%-346.1%+436.1%
10Y-1,202.4%-477.5%-724.9%
4.3.2.2. Operating Ratio

Measures how efficient Processa Pharmaceuticals Inc is keepingΒ operating costsΒ low.

  • Below 1 is considered healthy (always compare toΒ Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Processa Pharmaceuticals Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.897+0.897
5Y-0.89710Y10.508-11.405
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.111-2.111
TTM-2.694-2.694
YOY-3.096-3.096
3Y-3.652-3.652
5Y-0.8974.745-5.642
10Y10.5086.614+3.894
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Processa Pharmaceuticals Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Processa Pharmaceuticals Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toΒ Biotechnology industry mean).
  • A Current Ratio of 2.93Β means the company has $2.93 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Processa Pharmaceuticals Inc:

  • The MRQ is 2.929. The company is able to pay all its short-term debts. +1
  • The TTM is 3.235. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ2.929TTM3.235-0.306
TTM3.235YOY9.757-6.522
TTM3.2355Y9.540-6.305
5Y9.54010Y5.341+4.199
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.9293.661-0.732
TTM3.2353.846-0.611
YOY9.7574.140+5.617
3Y7.0034.688+2.315
5Y9.5405.746+3.794
10Y5.3416.147-0.806
4.4.3.2. Quick Ratio

Measures if Processa Pharmaceuticals Inc is able to pay off Short-term Debt but only usingΒ theΒ most liquid assets.

  • Above 1 is considered healthy butΒ always compareΒ Processa Pharmaceuticals Inc to theΒ Biotechnology industry mean.
  • A Quick Ratio of 2.26Β means the company can pay off $2.26 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Processa Pharmaceuticals Inc:

  • The MRQ is 2.258. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 2.249. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ2.258TTM2.249+0.009
TTM2.249YOY8.540-6.290
TTM2.2495Y8.425-6.176
5Y8.42510Y4.915+3.510
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.2582.848-0.590
TTM2.2493.169-0.920
YOY8.5403.786+4.754
3Y5.8264.311+1.515
5Y8.4255.703+2.722
10Y4.9156.368-1.453
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Processa Pharmaceuticals Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %Β of Processa Pharmaceuticals IncΒ assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareΒ Processa Pharmaceuticals Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.27Β means that Processa Pharmaceuticals Inc assets areΒ financed with 26.7% credit (debt) and the remaining percentage (100% - 26.7%)Β is financed by its owners/shareholders.Β 

Let's take a look of the Debt to Asset Ratio trends of Processa Pharmaceuticals Inc:

  • The MRQ is 0.267. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.299. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.267TTM0.299-0.032
TTM0.299YOY0.112+0.187
TTM0.2995Y0.161+0.138
5Y0.16110Y41.376-41.214
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2670.329-0.062
TTM0.2990.349-0.050
YOY0.1120.331-0.219
3Y0.1760.340-0.164
5Y0.1610.349-0.188
10Y41.3760.379+40.997
4.5.4.2. Debt to Equity Ratio

Measures ifΒ Processa Pharmaceuticals Inc is able toΒ pay off its debts by usingΒ shareholders equity.

  • Below 2 is considered healthy butΒ always compareΒ Processa Pharmaceuticals Inc to theΒ Biotechnology industry mean.
  • A Debt to Equity ratio of 36.4% means that company has $0.36 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Processa Pharmaceuticals Inc:

  • The MRQ is 0.364. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.464. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.364TTM0.464-0.101
TTM0.464YOY0.127+0.337
TTM0.4645Y0.227+0.238
5Y0.22710Y1.494-1.267
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3640.379-0.015
TTM0.4640.437+0.027
YOY0.1270.414-0.287
3Y0.2420.450-0.208
5Y0.2270.464-0.237
10Y1.4940.515+0.979
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

MeasuresΒ how much money you payΒ for each share forΒ every $1 in earnings Processa Pharmaceuticals Inc generates.

  • Above 15 is considered overpriced butΒ always compareΒ Processa Pharmaceuticals Inc to theΒ Biotechnology industry mean.
  • A PE ratio of -0.85 means the investor is paying $-0.85Β for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Processa Pharmaceuticals Inc:

  • The EOD is -0.523. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.855. Based on the earnings, the company is expensive. -2
  • The TTM is -2.625. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.523MRQ-0.855+0.332
MRQ-0.855TTM-2.625+1.770
TTM-2.625YOY-2.156-0.468
TTM-2.6255Y-10.980+8.355
5Y-10.98010Y-30.030+19.051
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.523-2.356+1.833
MRQ-0.855-2.077+1.222
TTM-2.625-2.574-0.051
YOY-2.156-3.760+1.604
3Y-2.430-3.773+1.343
5Y-10.980-6.193-4.787
10Y-30.030-6.876-23.154
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Processa Pharmaceuticals Inc:

  • The EOD is -0.543. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.888. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -2.584. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.543MRQ-0.888+0.345
MRQ-0.888TTM-2.584+1.696
TTM-2.584YOY-2.774+0.191
TTM-2.5845Y94.003-96.587
5Y94.00310Y5.727+88.276
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.543-3.246+2.703
MRQ-0.888-2.705+1.817
TTM-2.584-3.704+1.120
YOY-2.774-4.402+1.628
3Y-3.228-5.070+1.842
5Y94.003-8.477+102.480
10Y5.727-9.305+15.032
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofΒ Processa Pharmaceuticals Inc is to cheap or to expensiveΒ compared to its book value.

  • At or below 1 is considered healthyΒ (always compare to Biotechnology industry mean).
  • A PB ratio of 2.75 means the investor is paying $2.75Β for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Processa Pharmaceuticals Inc:

  • The EOD is 1.680. Based on the equity, the company is underpriced. +1
  • The MRQ is 2.748. Based on the equity, the company is underpriced. +1
  • The TTM is 8.946. Based on the equity, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD1.680MRQ2.748-1.068
MRQ2.748TTM8.946-6.197
TTM8.946YOY2.767+6.179
TTM8.9465Y9.122-0.176
5Y9.12210Y15.182-6.061
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1.6802.038-0.358
MRQ2.7481.843+0.905
TTM8.9462.125+6.821
YOY2.7672.442+0.325
3Y4.9252.492+2.433
5Y9.1223.652+5.470
10Y15.1824.311+10.871
4.6.2. Total Gains per Share

2.4. Latest News of Processa Pharmaceuticals Inc

Does Processa Pharmaceuticals Inc still have the same value as the quarterly reports suggest? Recent changes may be an indication that the value of the company is changing. Read the news from Processa Pharmaceuticals Inc to keep up to date. Note: the news is often already included in the price.

DateTitleRead
2025-06-13
14:00
Processa Pharmaceuticals to Engage Potential Partners and Investors at BIO International Convention 2025Read

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Processa Pharmaceuticals Inc.

4.8.1. Institutions holding Processa Pharmaceuticals Inc

Institutions are holding 9.051% of the shares of Processa Pharmaceuticals Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-03-31Armistice Capital, LLC0.47120.000356000560000
2025-03-31Virtu Financial LLC0.36370.000943229432290
2025-03-31Geode Capital Management, LLC0.28960344131243156.5508
2025-03-31Vanguard Group Inc0.205602443300
2025-03-31Miracle Mile Advisors, INC.0.08410.00011000000
2025-03-31Tower Research Capital LLC0.02080246750.2031
2025-03-31Wells Fargo & Co0.0013015400
2025-03-31UBS Group AG0.0005056-7852-99.2919
2025-03-31Bank of America Corp0.00030371248
2024-12-31Hanson Mcclain Inc000-85-100
2024-12-31Northern Trust Investments N A000-642-100
2024-12-31Absolute Investment Management LLC000-1-100
2025-03-31HRT FINANCIAL LLC000-31971-100
Total 1.43710.0013170789+71126+41.6%

4.9.2. Funds holding Processa Pharmaceuticals Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-04-30Fidelity Extended Market Index0.246102924200
2025-05-31Vanguard Institutional Extnd Mkt Idx Tr0.205602443300
2025-04-30Fidelity Series Total Market Index0.03820453600
2025-03-31NT Ext Equity Mkt Idx Fd - L0.00880104800
2025-03-31Northern Trust Extended Eq Market Idx0.00880104800
2025-05-31State St US Extended Mkt Indx NL Cl C0.0045053500
2025-04-30Fidelity Total Market Index0.0037044100
2025-03-31NT Ext Equity Mkt Idx Fd - NL0.0026031200
2025-03-31NT Ext Eq Mkt Indx Fd DC Lending Tier 50.0021025220.8
2024-12-31NT Ext Eq Mkt Indx Fd DC Lend T30.002102502500
2024-12-31NT Ext Eq Mkt Indx Fd DC Lend T40.002102502500
2025-03-31NT Ext Equity Mkt Idx Fd - DC - NL - T20.0020243-4-1.6194
2025-03-31SSgA U.S. Total Market Index Strategy0.0019022452.2831
2025-04-30Spartan Total Market Index Pool G0.0016019400
2025-05-31State St US Ttl Mkt Indx NL Cl A0.000506500
2025-03-31Northern Trust Wilshire 50000.000404600
Total 0.531063119+503+0.8%

5.3. Insider Transactions

Insiders are holding 11.604% of the shares of Processa Pharmaceuticals Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2025-01-27David YoungBUY1245000.8
2025-01-27George K NgBUY872000.8
2025-01-27Justin W YorkeBUY124000.8
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2025-03-31. Currency in USD. All numbers in thousands.

Summary
Total Assets4,810
Total Liabilities1,283
Total Stockholder Equity3,527
 As reported
Total Liabilities 1,283
Total Stockholder Equity+ 3,527
Total Assets = 4,810

Assets

Total Assets4,810
Total Current Assets3,758
Long-term Assets994
Total Current Assets
Cash And Cash Equivalents 2,897
Other Current Assets 861
Total Current Assets  (as reported)3,758
Total Current Assets  (calculated)3,758
+/-0
Long-term Assets
Property Plant Equipment 52
Long-term Assets Other 941
Long-term Assets  (as reported)994
Long-term Assets  (calculated)994
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities1,283
Long-term Liabilities0
Total Stockholder Equity3,527
Total Current Liabilities
Short-term Debt 50
Accounts payable 553
Other Current Liabilities 681
Total Current Liabilities  (as reported)1,283
Total Current Liabilities  (calculated)1,283
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)0
Long-term Liabilities  (calculated)0
+/-0
Total Stockholder Equity
Common Stock1
Retained Earnings -90,054
Other Stockholders Equity 93,580
Total Stockholder Equity (as reported)3,527
Total Stockholder Equity (calculated)3,527
+/-0
Other
Capital Stock1
Cash and Short Term Investments 2,897
Common Stock Shares Outstanding 9,527
Liabilities and Stockholders Equity 4,810
Net Debt -2,847
Net Invested Capital 3,527
Net Working Capital 2,475
Property Plant and Equipment Gross 52
Short Long Term Debt Total 50



5.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-31
> Total Assets 
0
0
0
4,352
3,884
3,185
3,467
3,843
2,938
2,908
2,785
2,667
2,542
2,543
878
498
498
47
43
35
3
104
3
80
2,983
12,886
14,438
13,463
13,215
12,078
11,306
10,821
10,883
10,012
10,011
9,589
25,214
33,338
31,138
29,025
26,464
24,301
21,658
18,604
8,620
12,432
10,090
8,083
5,787
9,945
7,601
4,942
3,229
4,810
4,8103,2294,9427,6019,9455,7878,08310,09012,4328,62018,60421,65824,30126,46429,02531,13833,33825,2149,58910,01110,01210,88310,82111,30612,07813,21513,46314,43812,8862,98380310433543474984988782,5432,5422,6672,7852,9082,9383,8433,4673,1853,8844,352000
   > Total Current Assets 
0
0
0
1,536
1,157
554
938
1,313
515
478
466
401
379
497
479
323
323
47
43
35
3
104
3
80
2,952
1,844
3,594
2,801
2,020
1,543
990
725
1,007
357
577
376
16,203
24,546
22,566
20,670
18,327
16,384
13,961
10,887
8,387
12,219
9,897
7,907
5,632
9,800
7,478
4,838
1,874
3,758
3,7581,8744,8387,4789,8005,6327,9079,89712,2198,38710,88713,96116,38418,32720,67022,56624,54616,2033765773571,0077259901,5432,0202,8013,5941,8442,95280310433543473233234794973794014664785151,3139385541,1571,536000
       Cash And Cash Equivalents 
0
0
0
1,392
1,027
421
630
1,002
187
82
40
56
21
42
15
15
15
2
15
7
3
2
3
80
2,847
1,777
2,850
2,424
1,741
1,249
722
504
692
142
453
325
15,416
23,048
20,831
19,093
16,498
14,395
12,064
9,055
6,504
10,742
8,677
6,861
4,706
8,920
5,571
2,891
1,191
2,897
2,8971,1912,8915,5718,9204,7066,8618,67710,7426,5049,05512,06414,39516,49819,09320,83123,04815,4163254531426925047221,2491,7412,4242,8501,7772,84780323715215151542215640821871,0026304211,0271,392000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,020
0
0
496
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000000496001,02000000000000000000000000
       Net Receivables 
0
0
0
49
30
20
61
24
19
20
99
27
4
91
104
12
12
25
25
25
0
0
25
9
63
27
164
95
22
47
0
1
0
28
26
8
232
74
70
70
70
0
0
0
0
0
0
0
0
22
0
0
0
0
0000220000000070707074232826280104722951642763925002525251212104914279920192461203049000
       Other Current Assets 
0
0
0
48
50
50
48
80
80
112
121
117
0
42
33
115
0
20
4
4
0
102
4
0
0
40
84
282
258
247
268
220
316
186
98
43
555
1,424
1,664
1,507
1,759
1,989
1,897
1,832
1,883
1,478
1,220
1,047
926
858
1,907
1,947
682
861
8616821,9471,9078589261,0471,2201,4781,8831,8321,8971,9891,7591,5071,6641,4245554398186316220268247258282844000410204420011533420117121112808048505048000
   > Long-term Assets 
0
0
0
2,816
2,727
2,631
2,530
2,530
2,423
2,429
2,319
2,266
0
2,046
399
176
176
0
0
0
0
0
0
28
0
11,043
10,844
10,662
10,461
10,535
10,316
10,096
9,876
9,656
9,435
9,213
9,012
8,792
8,572
8,355
8,136
7,917
7,697
7,718
233
213
193
175
154
144
123
104
1,356
994
9941,3561041231441541751932132337,7187,6977,9178,1368,3558,5728,7929,0129,2139,4359,6569,87610,09610,31610,53510,46110,66210,84411,0430280000001761763992,04602,2662,3192,4292,4232,5302,5302,6312,7272,816000
       Property Plant Equipment 
0
0
0
316
316
310
297
387
370
465
444
480
0
439
399
176
0
0
0
0
0
0
0
22
4
24
22
19
17
291
270
249
228
206
184
162
159
138
117
96
74
52
29
247
228
208
188
170
149
139
117
98
76
52
527698117139149170188208228247295274961171381591621842062282492702911719222442200000001763994390480444465370387297310316316000
       Intangible Assets 
0
0
0
2,500
2,411
2,321
2,232
2,143
2,054
1,964
1,875
1,786
1,696
1,607
0
0
0
0
0
0
0
0
0
0
0
11,013
10,816
10,637
10,438
10,239
10,040
9,841
9,642
9,444
9,245
9,046
8,847
8,648
8,449
8,254
8,057
7,860
7,662
7,465
0
0
0
0
0
0
0
0
0
0
00000000007,4657,6627,8608,0578,2548,4498,6488,8479,0469,2459,4449,6429,84110,04010,23910,43810,63710,81611,013000000000001,6071,6961,7861,8751,9642,0542,1432,2322,3212,4112,500000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-28
1
1
1
6
734
6
6
6
6
6
6
6
164
6
6
6
6
6
6
6
0
0
6
0
0
0
0
0
0
58
58000000600666666616466666667346111-2800000000000000000000000
> Total Liabilities 
0
0
0
1,296
1,322
1,449
2,457
1,466
1,267
1,878
2,162
2,783
1,334
1,841
2,198
2,116
2,116
2,165
2,214
2,285
2,354
2,083
2,354
115
2,610
5,610
3,131
2,957
3,514
2,954
2,804
2,151
2,871
2,778
3,418
4,062
2,275
2,002
1,896
1,817
978
1,064
1,576
1,364
1,149
2,290
931
915
797
1,061
1,577
1,221
1,533
1,283
1,2831,5331,2211,5771,0617979159312,2901,1491,3641,5761,0649781,8171,8962,0022,2754,0623,4182,7782,8712,1512,8042,9543,5142,9573,1315,6102,6101152,3542,0832,3542,2852,2142,1652,1162,1162,1981,8411,3342,7832,1621,8781,2671,4662,4571,4491,3221,296000
   > Total Current Liabilities 
0
0
0
181
716
1,100
2,365
1,310
1,122
785
562
809
840
1,722
2,093
2,089
2,089
2,165
2,214
2,285
2,354
2,083
2,354
115
2,600
2,848
650
691
646
725
783
292
1,192
1,246
1,898
2,658
1,221
1,096
1,161
1,226
971
1,058
1,571
1,193
999
2,161
821
826
731
1,011
1,552
1,219
1,533
1,283
1,2831,5331,2191,5521,0117318268212,1619991,1931,5711,0589711,2261,1611,0961,2212,6581,8981,2461,1922927837256466916502,8482,6001152,3542,0832,3542,2852,2142,1652,0892,0892,0931,7228408095627851,1221,3102,3651,100716181000
       Short-term Debt 
0
0
0
27
527
777
2,018
1,040
631
542
294
535
466
1,292
1,585
1,626
1,626
1,382
1,612
1,612
1,612
1,366
1,612
1,687
2,449
2,485
224
228
230
289
308
77
880
882
1,449
1,632
205
242
92
93
71
49
27
76
79
81
82
83
84
90
93
95
73
50
507395939084838281797627497193922422051,6321,449882880773082892302282242,4852,4491,6871,6121,3661,6121,6121,6121,3821,6261,6261,5851,2924665352945426311,0402,01877752727000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
230
230
0
803
804
1,377
1,553
118
145
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000001451181,5531,377804803023023000000000000000000000000000000
       Accounts payable 
0
0
0
102
73
161
233
101
77
83
112
145
0
178
219
191
0
169
174
171
0
159
166
96
8
105
251
80
292
283
143
65
76
93
73
427
321
177
288
355
219
316
648
311
328
317
239
346
312
455
953
712
881
553
5538817129534553123462393173283116483162193552881773214277393766514328329280251105896166159017117416901912191780145112837710123316173102000
       Other Current Liabilities 
0
0
0
52
115
162
114
168
413
160
155
130
0
109
124
249
0
614
427
502
0
557
576
20
0
258
174
383
124
153
333
72
235
272
376
598
695
676
688
686
610
643
870
729
513
1,682
419
314
252
466
412
413
579
681
6815794134124662523144191,6825137298706436106866886766955983762722357233315312438317425802057655705024276140249124109013015516041316811416211552000
   > Long-term Liabilities 
0
0
0
1,115
606
349
92
156
145
1,094
1,600
1,974
0
119
105
28
28
0
0
0
0
0
0
0
0
2,762
2,481
2,266
2,134
2,229
2,020
1,859
1,679
1,532
1,521
1,404
1,054
906
735
591
7
6
5
172
151
129
109
89
67
51
26
2
0
0
002265167891091291511725675917359061,0541,4041,5211,5321,6791,8592,0202,2292,1342,2662,4812,76200000000282810511901,9741,6001,094145156923496061,115000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
45
18
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000001845000000000000000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
2
440
372
2,266
2,134
2,004
1,833
1,692
1,532
1,404
1,316
1,245
931
841
704
582
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000005827048419311,2451,3161,4041,5321,6921,8332,0042,1342,2663724402100000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
531
441
304
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000304441531000000000000000000000000000000000000
> Total Stockholder Equity
0
0
0
3,056
2,562
1,735
1,010
2,377
1,671
1,030
623
-117
0
702
-1,320
-1,618
0
-2,118
-2,170
-2,250
0
-1,979
-2,351
-35
57
7,276
11,307
10,506
9,701
9,124
8,502
8,671
8,013
7,234
6,593
5,527
22,939
31,336
29,242
27,208
25,485
23,237
20,082
17,240
7,471
10,142
9,160
7,168
4,989
8,883
6,024
3,721
1,696
3,527
3,5271,6963,7216,0248,8834,9897,1689,16010,1427,47117,24020,08223,23725,48527,20829,24231,33622,9395,5276,5937,2348,0138,6718,5029,1249,70110,50611,3077,27657-35-2,351-1,9790-2,250-2,170-2,1180-1,618-1,3207020-1176231,0301,6712,3771,0101,7352,5623,056000
   Common Stock
0
0
0
0
0
0
1
1
1
1
1
1
0
1
1
1
0
1
1
1
0
1
1
2
1
4
4
4
4
4
4
4
1
1
1
1
1
2
2
2
2
2
2
2
2
2
2
2
0
0
0
0
0
1
100000222222222221111144444441211011101110111111000000
   Retained Earnings Total Equity000000000000000-30,652-27,495-25,396000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
-6
-19
-32
-46
-60
-77
-103
-127
-149
-186
-215
-243
-172
-172
-19
-19
-19
-19
-19
-19
2,267
-3
-5
-7
-10
-1,800
-1,685
-16
-18
-20
-22
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000-22-20-18-16-1,685-1,800-10-7-5-32,267-19-19-19-19-19-19-172-172-243-215-186-149-127-103-77-60-46-32-19-6000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
48,334
58,830
59,892
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000059,89258,83048,334000000000000000000000000000000000000
   Treasury Stock000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
5,666
5,993
6,012
6,042
8,335
8,484
9,248
9,753
10,034
0
14,261
14,544
14,482
0
12,917
12,922
12,922
0
12,933
12,903
16,999
0
12,229
17,465
17,517
17,321
17,495
17,842
18,874
18,994
19,090
19,182
21,188
48,334
58,830
59,892
60,846
62,307
63,286
65,295
68,474
71,717
78,409
80,039
80,130
80,358
86,979
87,129
88,211
88,915
93,580
93,58088,91588,21187,12986,97980,35880,13080,03978,40971,71768,47465,29563,28662,30760,84659,89258,83048,33421,18819,18219,09018,99418,87417,84217,49517,32117,51717,46512,229016,99912,90312,933012,92212,92212,917014,48214,54414,261010,0349,7539,2488,4848,3356,0426,0125,9935,666000



5.3. Balance Sheets

Currency in USD. All numbers in thousands.




5.4. Cash Flows

Currency in USD. All numbers in thousands.




5.5. Income Statements

Currency in USD. All numbers in thousands.


5.6. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue0
Cost of Revenue-0
Gross Profit00
 
Operating Income (+$)
Gross Profit0
Operating Expense-12,051
Operating Income-12,051-12,051
 
Operating Expense (+$)
Research Development7,269
Selling General Administrative4,782
Selling And Marketing Expenses0
Operating Expense12,05112,051
 
Net Interest Income (+$)
Interest Income201
Interest Expense-0
Other Finance Cost-0
Net Interest Income201
 
Pretax Income (+$)
Operating Income-12,051
Net Interest Income201
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-11,850-12,252
EBIT - interestExpense = 0
-11,850
-11,850
Interest Expense0
Earnings Before Interest and Taxes (EBIT)0-11,850
Earnings Before Interest and Taxes (EBITDA)-11,849
 
After tax Income (+$)
Income Before Tax-11,850
Tax Provision-0
Net Income From Continuing Ops-11,850-11,850
Net Income-11,850
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net201-201
 

Technical Analysis of Processa Pharmaceuticals Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Processa Pharmaceuticals Inc. The general trend of Processa Pharmaceuticals Inc is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Processa Pharmaceuticals Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Processa Pharmaceuticals Inc Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

SupportΒ is a price level at which demand for an asset is strong enough to prevent the price from falling further.
ResistanceΒ is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Processa Pharmaceuticals Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 0.47 < 0.5598 < 0.708.

The bearish price targets are: 0.15.

Know someone who trades $PCSA? Share this with them.πŸ‘‡

Processa Pharmaceuticals Inc Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theΒ moving averageΒ of the selected period.

  • Moving averages are laggingΒ trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Processa Pharmaceuticals Inc. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Processa Pharmaceuticals Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theΒ momentumΒ of theΒ selected period based on two moving averages.

  • MACD is aΒ lagging momentumΒ indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Processa Pharmaceuticals Inc. The current macd is -0.01688935.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Processa Pharmaceuticals Inc price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Processa Pharmaceuticals Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Processa Pharmaceuticals Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Processa Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) ChartProcessa Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Processa Pharmaceuticals Inc. The current adx is 52.96.

The long score for the Directional Movement Index (DMI) is 3/7.
The longshort score for the Directional Movement Index (DMI) is 3/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Processa Pharmaceuticals Inc shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bullish trend. The ADX is declining, the bullish trend is weakening. Could be a potential reversal to the downside. +2
Processa Pharmaceuticals Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • ShowsΒ the current trend.
  • ShowsΒ potential entry signals.
  • ShowsΒ Β potential exit signals.
  • Can be used to placeΒ trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Processa Pharmaceuticals Inc. The current sar is 0.47443252.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Processa Pharmaceuticals Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumΒ indicator, meaning the signals are instant.
  • RangesΒ between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Processa Pharmaceuticals Inc. The current rsi is 46.57. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Processa Pharmaceuticals Inc Daily Relative Strength Index (RSI) ChartProcessa Pharmaceuticals Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

ComparesΒ a certain price to multiple prices ranging over time.

  • LeadingΒ momentumΒ indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • RangesΒ between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Processa Pharmaceuticals Inc. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 1/6.
The longshort score for the Stochastic Oscillator is -2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Processa Pharmaceuticals Inc price going down in the near term. -2
  • Trending up: The STOCH %K is trending up. +1
Processa Pharmaceuticals Inc Daily Stochastic Oscillator ChartProcessa Pharmaceuticals Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,Β the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Processa Pharmaceuticals Inc. The current cci is -30.66408769.

Processa Pharmaceuticals Inc Daily Commodity Channel Index (CCI) ChartProcessa Pharmaceuticals Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Processa Pharmaceuticals Inc. The current cmo is -4.93536888.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Processa Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) ChartProcessa Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

Β Shows the current price relative to the highest high over the last 14 days.
Β 

  • Lagging momentum indicator
  • Ranging between 0 andΒ -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Processa Pharmaceuticals Inc. The current willr is -66.03325416.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Processa Pharmaceuticals Inc is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Processa Pharmaceuticals Inc Daily Williams %R ChartProcessa Pharmaceuticals Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldΒ 

Score

Let's take a look at the Bollinger Bands of Processa Pharmaceuticals Inc.

Processa Pharmaceuticals Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Processa Pharmaceuticals Inc. The current atr is 0.05386309.

Processa Pharmaceuticals Inc Daily Average True Range (ATR) ChartProcessa Pharmaceuticals Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Β Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Processa Pharmaceuticals Inc. The current obv is 986,232,860.

Processa Pharmaceuticals Inc Daily On-Balance Volume (OBV) ChartProcessa Pharmaceuticals Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Processa Pharmaceuticals Inc. The current mfi is 55.16.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Processa Pharmaceuticals Inc Daily Money Flow Index (MFI) ChartProcessa Pharmaceuticals Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Processa Pharmaceuticals Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-02-19WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-02-20SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-02-21BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-02-24STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-03STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-03-04STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-07STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-10STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-11STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-13STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-18STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-19STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-20MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-03-24RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2025-03-25STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-31STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-01SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-04-02MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-04-04RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-07STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-04-08WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-09STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-11STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-14DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-04-16STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-17DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-04-23MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2025-04-24MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-04-25STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-30SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-02STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-05DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-05-06CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-05-08CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-05-09STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-13MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-05-15STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-05-16STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-05-19STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-05-20CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-05-21STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-23SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-27STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-28WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-05-29SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-05-30STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-03WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-04SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-05STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-09STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-10CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-06-12RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-13CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-06-16MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-06-17SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-06-18STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-20STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-23STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-24CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-25CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-26SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-06-27BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-07-01STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-02STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-03STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-09CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-07-10CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-07-11MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

Processa Pharmaceuticals Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Processa Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5046.567
Ma 20Greater thanMa 500.240
Ma 50Greater thanMa 1000.259
Ma 100Greater thanMa 2000.325
OpenGreater thanClose0.220
Total0/5 (0.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Processa Pharmaceuticals Inc with someone you think should read this too:
  • Are you bullish or bearish on Processa Pharmaceuticals Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Processa Pharmaceuticals Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Processa Pharmaceuticals Inc

I send you an email if I find something interesting about Processa Pharmaceuticals Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Processa Pharmaceuticals Inc.

Receive notifications about Processa Pharmaceuticals Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.